Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.

Gene therapy - 1 Jul 2000

Marthinet E, Divita G, Bernaud J, Rigal D, Baggetto L G

Abstract excerpt

Multidrug resistance of cancer (MDR) is the major cause of failure of chemotherapy. The typical MDR phenotype is due to the overexpression of membrane proteins among which the main representative is P-glycoprotein (Pgp) encoded by the MDR1 gene. Many attempts to modulate MDR by chemosensitizers have been unsuccessful in human therapy due to their intrinsic toxic effects. In an effort to modulate the MDR phenotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Drug Resistance, Multiple

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endodeoxyribonucleases

Share to Genes, MDR

Share to Genetic Vectors

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Promoter Regions, Genetic

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 10918491
DOI: 10.1038/sj.gt.3301231

Genes

MPG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.PMID 10918491Read ↗

Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope?Semantic proximity Read ↗

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancersSemantic proximity Read ↗

Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy.Semantic proximity Read ↗

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesSemantic proximity Read ↗

Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1.Semantic proximity Read ↗

An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer ChemotherapySemantic proximity Read ↗

Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.Semantic proximity Read ↗

Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell typeSemantic proximity Read ↗

MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug ResistanceSemantic proximity Read ↗

Microparticle-associated nucleic acids mediate trait dominance in cancer.Semantic proximity Read ↗

Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cellsSemantic proximity Read ↗

Classical multidrug resistance in acute myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.